Approximately 20% to 30% of all people who suffer from psoriasis also develop painful inflammation in their joints over time.
Topline data were announced from a phase 3b trial evaluating the concomitant use of ixekizumab and tirzepatide in active PsA and obesity.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback